Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
58 hedge funds and large institutions have $419M invested in Adverum Biotechnologies in 2014 Q3 according to their latest regulatory filings, with 58 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$99.3M |
| 2 |
DM
Deerfield Management
New York
|
+$60.9M |
| 3 |
VM
VHCP Management
New York
|
+$41.1M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$30.7M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$21.8M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BG
51
BlackRock Group
London,
United Kingdom
| $167K | +$145K | +489 | New |
|
|
SO
52
STRS Ohio
Columbus,
Ohio
| $82K | +$71.4K | +240 | New |
|
|
CG
53
Colony Group
Boston,
Massachusetts
| $36K | +$31.5K | +106 | New |
|
54
Citigroup
New York
| $18K | +$15.5K | +52 | New |
|
|
SSG
55
Summit Securities Group
New York
| $16K | +$14.3K | +48 | New |
|
56
BlackRock
New York
| $7K | +$5.95K | +20 | New |
|
|
TRCT
57
Tower Research Capital (TRC)
New York
| $7K | +$5.95K | +20 | New |
|
|
SM
58
Sabby Management
Miami Beach,
Florida
| $1.71K | +$1.49M | +5,000 | New |
|
ADVM Hedge Fund Activity: Q3 2014 in Review
58 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q3 2014, worth a combined $419M.
Buyers outnumbered sellers: 58 funds opened new ADVM positions and 0 closed out — a net gain of 58 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $99.3M.
- 58 institutional investors held Adverum Biotechnologies (ADVM) as of Q3 2014, up from 0 in Q2 2014.
- Funds reported $419M of Adverum Biotechnologies stock for Q3 2014.
- 58 funds opened new Adverum Biotechnologies positions in Q3 2014 and 0 closed out, a net change of +58 holders.
- The largest Adverum Biotechnologies buyer in Q3 2014 was Fidelity Investments, an estimated $99.3M added.
Based on aggregated 13F filings for Q3 2014.